LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between LUNG BIOTECHNOLOGY PBC and COLLPLANT LTD. Dated as of October 19, 2018License, Development and Commercialization Agreement • October 25th, 2018 • CollPlant Holdings Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • Delaware
This License, Development and Commercialization Agreement (this “Agreement”) is dated as of October 19, 2018 (the “Execution Date”), by and between CollPlant Ltd. (“CollPlant”), a company organized and existing under the laws of Israel and having its principal place of business at 3 Sapir Street, Weizmann Science Park, P.O.B. 4132, Ness-Ziona 74140, Israel, and Lung Biotechnology PBC (“LB”), a public benefit corporation and wholly-owned subsidiary of United Therapeutics Corporation, a company organized and existing under the laws of the State of Delaware, U.S.A., and having its principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910, U.S.A. (each of CollPlant and LB individually referred to as a “Party” and collectively as the “Parties”).
